Pacira BioSciences, Inc.
Pacira BioSciences, Inc. Fundamental Analysis
Pacira BioSciences, Inc. (PCRX) shows weak financial fundamentals with a PE ratio of 47.26, profit margin of 2.99%, and ROE of 2.80%. The company generates $0.7B in annual revenue with moderate year-over-year growth of 3.85%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 37.3/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PCRX's fundamental strength across five key dimensions:
Efficiency Score
WeakPCRX struggles to generate sufficient returns from assets.
Valuation Score
ModeratePCRX shows balanced valuation metrics.
Growth Score
WeakPCRX faces weak or negative growth trends.
Financial Health Score
ExcellentPCRX maintains a strong and stable balance sheet.
Profitability Score
ModeratePCRX maintains healthy but balanced margins.
Key Financial Metrics
Is PCRX Expensive or Cheap?
P/E Ratio
PCRX trades at 47.26 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, PCRX's PEG of 0.41 indicates potential undervaluation.
Price to Book
The market values Pacira BioSciences, Inc. at 1.39 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.82 times EBITDA. This is generally considered low.
How Well Does PCRX Make Money?
Net Profit Margin
For every $100 in sales, Pacira BioSciences, Inc. keeps $2.99 as profit after all expenses.
Operating Margin
Core operations generate 5.80 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $2.80 in profit for every $100 of shareholder equity.
ROA
Pacira BioSciences, Inc. generates $1.65 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Pacira BioSciences, Inc. produces operating cash flow of $138.17M, showing steady but balanced cash generation.
Free Cash Flow
Pacira BioSciences, Inc. generates strong free cash flow of $121.34M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $2.82 in free cash annually.
FCF Yield
PCRX converts 12.50% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
47.26
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.41
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.39
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.38
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.58
vs 25 benchmark
Current Ratio
Current assets to current liabilities
5.26
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.03
vs 25 benchmark
ROA
Return on assets percentage
0.02
vs 25 benchmark
ROCE
Return on capital employed
0.03
vs 25 benchmark
How PCRX Stacks Against Its Sector Peers
| Metric | PCRX Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 47.26 | 29.28 | Worse (Expensive) |
| ROE | 2.80% | 820.00% | Weak |
| Net Margin | 2.99% | -19743.00% (disorted) | Weak |
| Debt/Equity | 0.58 | 0.26 | Weak (High Leverage) |
| Current Ratio | 5.26 | 4.69 | Strong Liquidity |
| ROA | 1.65% | -17807.00% (disorted) | Weak |
PCRX outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Pacira BioSciences, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
49.45%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-711.30%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
141.08%
Industry Style: Defensive, Growth, Innovation
High Growth